In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...

An oft-mentioned advantage of ALGOL over FORTRAN is the recursion capability of the former. FORTRAN adherents often belittle this advantage by claiming that all recursive relations can be reduced to ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rallybio ...

Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – Rallybio Corporation (Nasdaq: RLYB), a ...

Factorial Energy, a U.S.-based leader in solid-state battery technology, has announced its first shipment of FEST® lithium-metal battery cells for drone use. The recipient is Avidrone Aerospace, a ...

Carmaker Stellantis announced on Thursday the successful validation of U.S. startup Factorial Energy's automotive-sized solid-state battery cells with FEST (Factorial Electrolyte System Technology).